Ipamorelin Side Effects and CJC-1295 Combo: What Trials Show
The trial gave intravenous doses to 114 bowel surgery patients, and any adverse event was less common on ipamorelin (87.5% vs 94.8%). CJC-1295 alone caused injection site reactions (about 70%), headache (63%), diarrhea (43%) and flushing or warmth (30%) in healthy adults after one dose. Water retention, hunger and tingling are user reports, not human trial findings (hunger has rodent data).
If you are comparing sources, the vendor scorecard shows which stores passed independent lab tests and which did not.
Ipamorelin's reputation is built on a selectivity claim: it triggers growth hormone release through the ghrelin receptor without dragging ACTH and cortisol along with it, unlike GHRP-6 and GHRP-2. That claim is well supported in animal pharmacology. It is not a substitute for human safety data, and ipamorelin has one published patient trial, run on hospitalized surgical patients who received it intravenously. CJC-1295, the GHRH analog it is most often paired with, has a little more: small trials in healthy adults. This page sorts what those trials recorded from what animal work suggests and from what is only user report.
Everything below is research use information. It is not medical advice, it is not a recommendation to start or stop anything, and none of it substitutes for supervision by a qualified clinician who can see your bloodwork and your history.
Ipamorelin and CJC-1295 Side Effects at a Glance
The table keeps three kinds of evidence apart: what a human trial recorded, what animal studies suggest, and what only shows up in reports from users. Percentages are the drug group, with placebo alongside where the source gives it.
| Reported effect | Compound and setting | What was recorded | Source |
|---|---|---|---|
| Human trial data | |||
| Low potassium (hypokalemia) | Ipamorelin, intravenous, bowel surgery inpatients (56 on drug, 58 on placebo) | 12.5% vs 3.4% on placebo | FDA review of Beck 2014 |
| Insomnia | Ipamorelin, same trial | 10.7% vs 5.2% | FDA review of Beck 2014 |
| High blood glucose at discharge | Ipamorelin, same trial | 14.3% vs 8.6% | FDA review of Beck 2014 |
| Nausea, vomiting, abdominal distention | Ipamorelin, same trial | Most common events in both arms, numerically lower on ipamorelin | FDA review of Beck 2014 |
| Any adverse event | Ipamorelin, same trial | 87.5% vs 94.8% | Beck 2014 |
| Serious adverse events and deaths | Ipamorelin, same trial | 17.9% vs 15.5%; two deaths on ipamorelin after anastomotic leak, relation to the drug unclear | FDA review of Beck 2014 |
| No adverse events stated | Ipamorelin, single 15 minute intravenous infusion, healthy men | The paper does not state any adverse events | Gobburu 1999, per FDA |
| Injection site reactions | CJC-1295, subcutaneous, healthy adults | About 70% after one dose, transient, with hardening lasting up to 5 days at higher doses; every actively treated subject in the multiple dose trial, all mild (mild redness also in 3 of 4 placebo subjects there) | Teichman 2006 |
| Headache | CJC-1295, single dose trial | 63% vs 14% on placebo | Teichman 2006 |
| Diarrhea | CJC-1295, single dose trial | 43%, more common at the two highest doses | Teichman 2006 |
| Flushing, warmth, brief low blood pressure | CJC-1295, healthy adults | 30% after one dose; flushing in 40% at the low and 100% at the high dose in the multiple dose trial | Teichman 2006 |
| Faster heart rate, injection site redness | CJC-1295, single dose, healthy men | Reported; heart rate rise was dose dependent; no serious events | Ionescu and Frohman 2006, per FDA |
| Nausea or abdominal pain | CJC-1295, multiple dose trial | 20%, in the CJC-1295 group only | FDA review of Teichman 2006 |
| Dizziness, low blood pressure, leg muscle contractions, loss of coordination | CJC-1295, multiple dose trial | Two subjects had transient dizziness and low blood pressure after a first dose; one had transient involuntary leg contractions and some loss of coordination | FDA review of Teichman 2006 |
| Cortisol, prolactin, TSH, LH | CJC-1295, single dose of 60 micrograms per kg, healthy adults | No significant increase | Teichman 2006, full text |
| Edema, joint pain, glucose intolerance | CJC-1295, healthy adults | Not seen in any subject | Teichman 2006, full text on Zenodo |
| Animal data | |||
| ACTH and cortisol | Ipamorelin, conscious pigs | Not raised beyond GHRH levels, even above 200 times the ED50; prolactin unchanged with every secretagogue tested | Raun 1998 |
| More food intake, weight and fat gain | Ipamorelin, rats (repeated intravenous doses) and mice | Significant rise in food intake and weight gain in rats; higher body fat in mice | Venkova 2009, Lall 2001 |
| Adverse event reports and user reports | |||
| Elbow joint pain | Compounded ipamorelin with sermorelin, two months | One FDA adverse event report; FDA says the combination means it cannot be pinned on ipamorelin | FDA review |
| Water retention, hunger, numbness or tingling in the hands, lethargy | Ipamorelin and CJC-1295, user reports | Anecdotal, no trial source; no reliable rate exists | None |
Two things stand out. The ipamorelin numbers come from sick surgical inpatients dosed intravenously, not healthy adults injecting under the skin, and the CJC-1295 numbers come from 66 healthy adults given one to three doses. Neither describes months of research use. And the effects people list most often online, water retention, hunger and tingling, are exactly the ones no human trial of either compound has measured.
The Selectivity Claim, and What It Rests On
Ipamorelin is a pentapeptide that activates the ghrelin receptor to trigger growth hormone release from the pituitary. Its reputation rests on a 1998 Novo Nordisk study (Raun and colleagues, European Journal of Endocrinology) showing that in conscious pigs, ipamorelin released growth hormone with a potency and peak response very close to GHRP-6, while ACTH and cortisol stayed at levels not significantly different from those seen after GHRH, the body's own growth hormone releasing hormone. That held even at doses more than two hundred times the ED50, the dose that produces half the maximal growth hormone response. In the same pigs, GHRP-6 and GHRP-2 both raised ACTH and cortisol. Prolactin is a different story from the one usually told: none of the secretagogues in that study, ipamorelin, GHRP-6 or GHRP-2, changed prolactin, LH, FSH or TSH. So the pig data separates ipamorelin from the older compounds on the cortisol axis; it does not show a prolactin difference either way.
The caveat is in the species and the dosing. That finding is animal pharmacology in pigs, not a result confirmed by a controlled human trial at the doses people actually run subcutaneously. FDA's 2024 review repeats the selectivity point, citing the pig work, but no human ipamorelin study it reviewed reports cortisol or prolactin results. "No significant cortisol rise in pigs at more than 200 times the ED50" and "confirmed safe in humans" are different claims, and the record only supports the first one directly.
Not sure which of these you actually need?
Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.
Build your stack, 2 minutesWhat the One Ipamorelin Trial Actually Found
Ipamorelin was first made by Novo Nordisk in the mid-1990s, according to FDA's 2024 review. It was later taken into a phase 2, randomized, double blind, placebo controlled trial for postoperative ileus, the temporary gut paralysis that follows bowel surgery, sponsored by Helsinn Therapeutics. The trial enrolled 117 hospitalized adults undergoing small or large bowel resection, with 114 in the safety population. Patients received 0.03 mg/kg by intravenous infusion twice daily from the first day after surgery until day 7 or discharge, 56 on ipamorelin and 58 on placebo. The primary endpoint was time to tolerating a standardized solid meal: a median 25.3 hours on ipamorelin versus 32.6 hours on placebo, not a statistically significant difference (p = 0.15), and the secondary measures did not separate either. The trial was published by Beck and colleagues in 2014 in the International Journal of Colorectal Disease, and FDA's review quotes a 2020 paper saying that after these disappointing results its development was discontinued.
The safety data from that trial is the only controlled patient adverse event record ipamorelin has, so it is worth stating plainly. Any treatment emergent adverse event occurred in 87.5 percent of the ipamorelin group versus 94.8 percent on placebo, meaning the drug group reported fewer, not more, adverse events overall. Nausea, vomiting and abdominal distention were the most common complaints in both arms, which fits a population recovering from bowel surgery. The authors concluded that ipamorelin at 0.03 mg/kg twice daily for up to 7 days "was well tolerated". Three findings did come in higher on ipamorelin than placebo: hypokalemia, 12.5 percent versus 3.4 percent, insomnia, 10.7 percent versus 5.2 percent, and high blood glucose at discharge, 14.3 percent versus 8.6 percent.
Serious adverse events, including infections, anastomotic leaks and readmissions for wound complications, occurred in 17.9 percent of the ipamorelin group (10 patients) and 15.5 percent on placebo (9 patients), most of them after dosing had ended. Two patients on ipamorelin died, both after bowel resection for colon cancer complicated by anastomotic leak. FDA's 2024 review of the trial, prepared for its Pharmacy Compounding Advisory Committee, says it is unclear whether those deaths were related to ipamorelin, but cites them together with the higher hypokalemia and hyperglycemia rates as a safety concern. Three patients in each arm stopped the drug early because of an adverse event; on ipamorelin the reasons were nausea, high blood pressure or low blood pressure.
Two caveats matter more than the numbers. First, this was intravenous dosing in hospital inpatients recovering from bowel surgery, a different exposure and a different population from subcutaneous use in a healthy adult, so the rates describe that setting and should not be read as the expected profile for research use. Second, a surgical population already runs a high baseline rate of nausea, vomiting, electrolyte shifts and sleep disruption, which is likely why even the placebo arm's adverse event rate was so high. The authors themselves call it a small proof of concept study, and with 56 patients on the drug each gap above comes down to a handful of people. Still, hypokalemia, insomnia and high glucose are where ipamorelin came in above placebo, and they are the closest thing to a specific human safety signal this compound has.
The only other human ipamorelin data in FDA's review is a 1999 pharmacokinetic study (Gobburu and colleagues, Pharmaceutical Research) in healthy male volunteers, eight per dose level, each given a single 15 minute intravenous infusion. It measured a half-life of about 2 hours and a single growth hormone pulse peaking at about 40 minutes. FDA notes the paper does not state any adverse events, which is not the same as showing there were none.
CJC-1295 Side Effects in Healthy Adults
CJC-1295 is a long acting GHRH analog: the form used in the human studies binds to albumin after injection, the form known as CJC-1295 with DAC, and FDA's 2024 CJC-1295 review notes the exact salt form was not specified. Teichman and colleagues (2006, Journal of Clinical Endocrinology and Metabolism) ran two randomized, double blind, placebo controlled trials in 66 healthy adults aged 21 to 61. The first gave single subcutaneous doses of 30, 60, 125 or 250 micrograms per kg; the second gave two or three weekly or every other week doses.
In the single dose trial, adverse events were reported in 33 of 35 people on CJC-1295 (94 percent) and 2 of 7 on placebo (29 percent), all mild to moderate. Injection site reactions (irritation, redness, hardening, pain or itching) occurred in about 70 percent, with hardening lasting up to five days at higher doses, and short-lived hive-like rashes at the site in almost 30 percent. Headache came in at 63 percent (14 percent on placebo), diarrhea at 43 percent, and flushing, warmth and brief low blood pressure at 30 percent, all more common at 125 and 250 micrograms per kg. In the multiple dose trial every actively treated subject had a mild injection site reaction (mild redness also appeared in three of four placebo subjects) and flushing rose from 40 percent at the low dose to 100 percent at the high dose. Three people left the two trials early: two because of mild injection site reactions and one after several mild effects following a single injection. No serious adverse reactions were reported, there were no consistent changes in glucose or other lab values, and the authors state that none of the subjects developed the edema, joint pain or glucose intolerance seen with growth hormone treatment itself. A single dose of 60 micrograms per kg did not significantly raise cortisol, prolactin, TSH or LH. The full text is available as a PDF on Zenodo.
A second study, Ionescu and Frohman (2006), gave healthy men aged 20 to 40 one injection of 60 or 90 micrograms per kg and found growth hormone pulses preserved, trough growth hormone up 7.5 fold and IGF-1 up 45 percent. FDA's review summarises its adverse events as a dose dependent rise in heart rate and short-lived injection site redness and tenderness, with no serious events.
The one longer patient study never reached print. FDA's review describes anecdotal reports of a phase 2 trial in 192 people with HIV lipodystrophy that was terminated after one participant had an acute heart attack two hours after his 11th weekly dose and died about an hour later; the attending physician's most likely explanation was undiagnosed coronary artery disease, and the data was never published. FDA's conclusion lists the adverse events seen across the healthy volunteer studies, including dizziness, low blood pressure, a faster heart rate and brief loss of coordination, and says some of them "warrant further study", for example in people at risk of falls or with heart disease. The CJC-1295 side effects page covers the compound on its own in more depth.
CJC-1295 and Ipamorelin Side Effects Together
The pairing is popular because the two work through different receptors: CJC-1295 through the GHRH receptor and ipamorelin through the ghrelin receptor. Nobody has published a controlled human trial of the combination. FDA's 2024 ipamorelin review found only one clinical study of ipamorelin that reported adverse events, the surgical trial above, and its CJC-1295 review lists only the healthy volunteer studies and the unpublished HIV trial. So the side effects of CJC-1295 and ipamorelin are, in practice, the two lists above added together, with no data on whether combining them makes any effect larger.
Two details change how to read that. The two compounds are not in the body for the same length of time: CJC-1295 with DAC had an estimated half-life of 5.8 to 8.1 days in Teichman's trial, against about 2 hours for ipamorelin in Gobburu's volunteer study. And the human studies used CJC-1295 with DAC; FDA's review says no clinical safety information was submitted or found for the other forms, including CJC-1295 (free base). In the single dose trial, headache and diarrhea occurred occasionally at various times during the 7 days after dosing, and the adverse events at the 250 microgram per kg dose resolved spontaneously after a few hours.
The CJC-1295 and ipamorelin stack page covers why the pair is used and what is and is not known about it, and the ipamorelin dosage guide covers the doses studies have used. If you are sourcing either for laboratory research, you can compare stores for ipamorelin or compare stores for the CJC-1295 and ipamorelin blend, and the CJC-1295 and ipamorelin calculator works out the syringe volume for a given vial and water amount. This is laboratory research use information only.
The Appetite Question
Ghrelin's other main job, besides triggering growth hormone, is stimulating hunger, and GHRP-6 has a strong reputation in research forums for a hunger spike after a dose. A common claim is that ipamorelin's selectivity extends to appetite and that it leaves hunger alone. The animal data does not support that. In a 2009 rat study of postoperative ileus (Venkova and colleagues, Journal of Pharmacology and Experimental Therapeutics), a single intravenous dose of ipamorelin had no effect on food intake over the following 48 hours, but repeated dosing over two days significantly increased food intake and body weight gain. In a 2001 mouse study (Lall and colleagues), twice daily ipamorelin raised body fat, and secretagogue treatment, unlike growth hormone itself, increased food intake.
So users who notice more hunger on ipamorelin are describing something with a documented basis in animals, not just expectation. What is missing is human data. The surgical trial listed an appetite assessment among its secondary measures, but neither the published abstract nor FDA's 2024 review of the trial reports an appetite difference between the arms, and there is no controlled comparison of how strongly ipamorelin and GHRP-6 drive hunger in people. The fair summary is that increased appetite is a plausible, animal-documented effect of ipamorelin whose size in humans has not been measured.
Injection Site Reactions
For subcutaneous ipamorelin there is no trial data at all: FDA's review found no pharmacokinetic or clinical data for the subcutaneous route, and the one patient trial was intravenous. For CJC-1295, injection site reactions were the most common adverse event in the healthy volunteer trials, at about 70 percent after one dose. So redness, itching or a small lump after an ipamorelin injection is plausible and often reported by users, but there is no measured rate for it. FDA also flags immunogenicity, an immune response to the peptide itself, as a concern for injected ipamorelin, noting that the subcutaneous route is generally associated with more immunogenicity than the intravenous one.
Rotating sites, letting the alcohol dry fully, allowing cold material to warm first, using a fresh needle, and keeping the injected volume small are the usual ways people reduce local irritation. The injection guide covers rotation and technique. A reaction that spreads, blisters, hardens into a lasting lump, or arrives with fever is not ordinary irritation and is a reason to see a clinician.
Water Retention, Tingling and Joint Aches
Puffy hands or face, a few pounds of scale weight in the first weeks, stiff joints and numbness or tingling in the fingers are among the most repeated complaints in user reports about growth hormone secretagogues. None of them has a trial rate for ipamorelin: they are not among the adverse events FDA's review lists from the surgical trial, and in the CJC-1295 trials the authors state that no subject developed edema or joint pain.
The reason people expect them is growth hormone itself. Fluid retention is in the warnings section of approved recombinant growth hormone labels, and FDA's ipamorelin review says it is concerned that similar risks will apply to secretagogues that raise growth hormone and IGF-1. The only formal report of a joint problem is a single FDA adverse event report: a 46 year old man using a compounded ipamorelin and sermorelin injection for two months reported elbow joint pain, and FDA notes that with two peptides in the product it cannot be pinned on ipamorelin. Treat water retention and tingling as plausible but anecdotal.
Glucose, Potassium and Sleep
Glucose. This one is real in principle for any growth hormone secretagogue: glucose intolerance and diabetes are on the growth hormone label risk list FDA cites. Ipamorelin's surgical trial did record a glucose signal, high blood glucose at discharge in 14.3 percent of the ipamorelin group versus 8.6 percent on placebo. That trial ran for days, not weeks, in patients under surgical stress that already disrupts glucose handling, so it says little about sustained use, but it points the same direction as the mechanism. The CJC-1295 trials, by contrast, found no consistent change in glucose.
Potassium. Hypokalemia, 12.5 percent versus 3.4 percent, was the largest relative gap in the surgical trial. Bowel surgery itself shifts electrolytes, so this may not carry over to healthy users, but it is the one laboratory signal ipamorelin has in humans and FDA cites it as a safety concern.
Sleep. Lethargy and sleepiness turn up in user reports, which are anecdotal, yet the only controlled data point runs the other way: insomnia in 10.7 percent on ipamorelin versus 5.2 percent on placebo, in a hospital setting where sleep is already poor. Neither direction has been tested in healthy adults. For the wider evidence on peptides and sleep, see the best peptides for sleep, ranked by evidence.
The Long Term Question, Stated Plainly
There is no multi year controlled follow up of ipamorelin or CJC-1295 in any population. The ipamorelin trial dosed for up to seven days around a hospital stay, development for postoperative ileus was discontinued, and the CJC-1295 trials ran 28 and 49 days with one to three doses. So the accurate statement is that long term side effects are unknown, not that they are absent. The question a long study would need to answer is the one FDA raises for all growth hormone secretagogues: whether the known risks of raised growth hormone and IGF-1, listed on approved growth hormone labels as neoplasm, glucose intolerance and diabetes, intracranial hypertension, fluid retention, hypoadrenalism, hypothyroidism and pancreatitis among others, apply to these compounds too.
FDA and WADA Status
Not FDA approved. FDA states that there are no FDA-approved drug products containing ipamorelin, and that CJC-1295 is not a component of any FDA-approved drug (ipamorelin review, CJC-1295 review).
Compounding. FDA's page on bulk drug substances that may present significant safety risks, current as of 22 April 2026, lists ipamorelin acetate in Category 2 under the 503B outsourcing facility policy, with a date of 29 September 2023, and also shows it and CJC-1295 in its table of substances nominated but withdrawn. FDA's stated risk for ipamorelin is immunogenicity and that "a study published in literature identified serious adverse events including death when ipamorelin was administered intravenously"; for CJC-1295 it says FDA "has identified serious adverse events", including increased heart rate and a systemic vasodilatory reaction. At the 29 October 2024 advisory committee meeting, members voted 0 yes, 12 no and 1 abstention on placing ipamorelin, free base and acetate, on the 503A bulks list, and at the 4 December 2024 meeting they voted 0 to 13 against CJC-1295 free base and 1 to 12 against CJC-1295 acetate. The research peptides legal status guide explains what these categories mean.
The 30 October 2026 HHS notice. HHS published a draft enforcement discretion policy for 503A compounding of certain peptides in the Federal Register. The notice text names no substances; they sit in an appendix on hhs.gov that would not open for us. A law firm summary lists six peptides (BPC-157, TB-500, Epitalon, Semax, KPV and MOTS-c), and neither ipamorelin nor CJC-1295 appears in it. The notice says the policy does not establish rights for anyone and is not binding on HHS or the public. The peptide enforcement tracker logs FDA actions as they are posted.
Outside the United States. In Australia, ABC News reported a coroner's finding that a March 2025 death followed injections of CJC-1295 and ipamorelin prescribed by a doctor; the coroner found the man was taking more than the prescribed dose. Separately, Victoria's health department reported 13 anaphylaxis cases associated with unapproved peptides since July 2025 and named no product. Our report sets out what each source says and what none of them says.
Sport. The 2026 WADA Prohibited List, as republished in the Dutch government gazette, names CJC-1295 under GHRH analogues and ipamorelin under growth hormone secretagogues, both in section S2.2.4, and prohibits the class at all times, in and out of competition.
Who the Known Risks Matter Most For
FDA's reviews give the clearest map. The growth hormone label risks above make an active or past cancer, diabetes or poor glucose control, and untreated thyroid or adrenal problems the obvious reasons for caution, since raising growth hormone and IGF-1 is the whole point of these compounds. The CJC-1295 findings on dizziness, low blood pressure and heart rate are the reason FDA singles out people at risk of falls and people with heart disease. There is no human data at all in pregnancy, breastfeeding or under eighteens. Anyone in those groups, or on medication that touches the endocrine system, belongs with a clinician rather than a forum thread.
There is also a risk that has nothing to do with the molecule. FDA's ipamorelin review describes the substance as not well characterized for compounding and notes that endotoxin testing for injectable use is lacking, and research chemical vials carry no assurance of identity, purity or sterility at all. The general peptide side effects page makes the case that supply quality is often the larger variable, which matters here because the one patient trial used a pharmaceutical intravenous formulation, not the research vials most people are actually injecting.
What the Human Signals Point To
The thin human record means the few signals that exist are worth knowing by name: potassium and glucose from the ipamorelin trial, and IGF-1, the marker the CJC-1295 studies tracked. Which tests make sense, and when, is a decision for a clinician who can see your history. Simple things to note yourself are injection sites and reactions, morning weight, ring or shoe fit as a crude fluid proxy, sleep quality, and any joint or hand symptoms with dates.
Frequently Asked Questions
What are the side effects of ipamorelin?
In the only published patient trial, intravenous ipamorelin in 56 bowel surgery patients, low potassium (12.5 percent versus 3.4 percent on placebo), insomnia (10.7 versus 5.2 percent) and high blood glucose at discharge (14.3 versus 8.6 percent) were more common than on placebo, while adverse events overall were lower (87.5 versus 94.8 percent). Two patients on ipamorelin died after anastomotic leaks, and FDA says the link to the drug is unclear. Injection site reactions, water retention, hunger and tingling are widely reported by users of subcutaneous ipamorelin, but no trial has measured them.
What are the side effects of CJC-1295 and ipamorelin?
No trial has tested the combination, so the honest answer is the two records added together. CJC-1295 trials in healthy adults recorded injection site reactions in about 70 percent after one dose, headache in 63 percent, diarrhea in 43 percent and flushing, warmth or brief low blood pressure in 30 percent, mostly at the higher doses. Ipamorelin's surgical trial adds low potassium, insomnia and high blood glucose. Whether combining the two changes any of these has not been studied.
Does ipamorelin raise cortisol or prolactin?
Not in the animal data. In a 1998 study in pigs, ipamorelin did not raise ACTH or cortisol beyond the levels seen after GHRH, even at more than 200 times the dose giving half the maximal growth hormone response, while GHRP-6 and GHRP-2 raised both. None of the secretagogues tested changed prolactin. No published human trial has reported cortisol or prolactin on ipamorelin, so this is well supported in animals rather than proven in people. For CJC-1295, a human trial found no significant rise in cortisol or prolactin after one dose.
Does ipamorelin cause water retention?
It may, but no trial has recorded it. Water retention comes from user reports and from what growth hormone itself does, which is why FDA lists fluid retention among the growth hormone risks it is concerned could apply to ipamorelin. It is not among the adverse events reported from ipamorelin's surgical trial, and in the CJC-1295 trials in healthy adults no subject developed edema. Treat it as plausible but unmeasured.
Does ipamorelin increase hunger?
It can in animals. In rats, repeated intravenous ipamorelin significantly increased food intake and body weight gain, and in mice ipamorelin increased body fat, with secretagogue treatment raising food intake. Ipamorelin acts on the ghrelin receptor, the receptor behind hunger signalling. No human trial has reported an appetite result, so increased hunger is plausible but its size in people is unknown.
Is ipamorelin FDA approved?
No. FDA states there are no FDA-approved drug products containing ipamorelin, and CJC-1295 is not a component of any FDA-approved drug. In October 2024 FDA's compounding advisory committee voted 12 to 0, with one abstention, against adding ipamorelin to the list of substances pharmacies may compound, and in December 2024 it voted against CJC-1295. FDA's Category 2 page still lists ipamorelin acetate among substances that may present significant safety risks under its outsourcing facility policy. Both are prohibited at all times on the 2026 WADA list.
Is ipamorelin safe long term?
Nobody knows. The only published patient trial dosed for up to seven days around bowel surgery, the healthy volunteer study used single 15 minute infusions, and development for postoperative ileus was discontinued, so there is no multi month or multi year data in any population. Long term effects are unknown rather than absent. The question a long study would need to answer is the one FDA raises for all growth hormone secretagogues: the known risks of raised growth hormone and IGF-1, including glucose intolerance and neoplasm.
How long do ipamorelin and CJC-1295 side effects last?
Trial data only covers CJC-1295. In the single dose trial, injection site reactions were transient, with hardening lasting up to 5 days at higher doses, and the adverse events at the highest dose resolved after a few hours; headache and diarrhea occurred occasionally during the 7 days after dosing. Ipamorelin's half-life was about 2 hours after an intravenous infusion in healthy men, but no trial has recorded how long any side effect lasts after a subcutaneous dose.
Sources (checked 1 November 2026)
- Beck et al. Ipamorelin for postoperative ileus in bowel resection patients, phase 2 trial. International Journal of Colorectal Disease, 2014. Checked 1 November 2026.
- Safety and efficacy of ipamorelin for management of post-operative ileus (NCT00672074), Helsinn Therapeutics. ClinicalTrials.gov. Checked 1 November 2026.
- FDA briefing document, ipamorelin-related bulk drug substances. Pharmacy Compounding Advisory Committee, 2024. Checked 1 November 2026.
- Gobburu et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers. Pharmaceutical Research, 1999. Checked 1 November 2026.
- Raun et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998. Checked 1 November 2026.
- Venkova et al. Efficacy of ipamorelin in a rodent model of postoperative ileus. Journal of Pharmacology and Experimental Therapeutics, 2009. Checked 1 November 2026.
- Lall et al. Growth hormone independent stimulation of adiposity by GH secretagogues. Biochemical and Biophysical Research Communications, 2001. Checked 1 November 2026.
- Teichman et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults. Journal of Clinical Endocrinology and Metabolism, 2006. Checked 1 November 2026.
- Teichman et al. 2006, full text PDF. Zenodo. Checked 1 November 2026.
- Ionescu and Frohman. Pulsatile secretion of GH persists during continuous stimulation by CJC-1295. Journal of Clinical Endocrinology and Metabolism, 2006. Checked 1 November 2026.
- FDA briefing document, CJC-1295-related bulk drug substances. Pharmacy Compounding Advisory Committee, 2024. Checked 1 November 2026.
- Certain bulk drug substances for use in compounding that may present significant safety risks. FDA, content current as of 22 April 2026. Checked 1 November 2026.
- Final summary minutes, Pharmacy Compounding Advisory Committee, 29 October 2024. FDA. Checked 1 November 2026.
- Final summary minutes, Pharmacy Compounding Advisory Committee, 4 December 2024. FDA. Checked 1 November 2026.
- Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. HHS, Federal Register, 30 October 2026. Checked 1 November 2026.
- HHS issues enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. BakerHostetler, 2026 (secondary summary of the policy's peptide list). Checked 1 November 2026.
- 2026 WADA Prohibited List, S2 peptide hormones, as republished in the Dutch government gazette (WADA's own PDF would not load when checked). Checked 1 November 2026.
- ABC News, 29 October 2026, report on the Victorian coroner's finding. Checked 1 November 2026.
- Anaphylaxis notifications associated with unapproved peptides in Victoria. Victorian Department of Health. Checked 1 November 2026.
Not sure which of these you actually need?
Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.
Build your stack, 2 minutes